Seven recommendations for sharing intellectual property, know-how and technology – report of Global Expert...
Negotiators of a Pandemic Treaty should heed the recommendations, published 15 July in the BMJ Global Health, to design a fair global system for...
WHO Fair Pricing Forum: Watching for Drug Industry Accountability
by Katrina Perehudoff and Jennifer Sellin
Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...
The Italian Exception – A personalised approach to accessing high-priced patented medicines
At the end of March 2017, the Italian Minister of Health Beatrice Lorenzin has authorised the importation of generic medicines. She did this with...
The € 7.4 billion for Covid-19 product and vaccine development needs a few strings...
On 4 May 2020, European Commission President Ursula von der Leyen hosted the Coronavirus Global Response conference, an on-line pledging event to accelerate the...
Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...
TRIPS, technology transfer and access to pandemic countermeasures: What the WHOÂ Pandemic Treaty must...
The scrambling for access to Covid-19 vaccines by developing countries has reignited the debate on the WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS)...
High medicines prices in Europe – do not Brexit the people
The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...
Updated TRIPS Flexibilities Database
In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...
Pharmaceutical Pricing Hostages
Ireland seems to be the stage of some of the most bizarre pharmaceutical company behaviour these days. This month, the pharmaceutical company CSL Behring...
It is not too late to solve the know-how problem in the WHO Pandemic...
Introduction
One of the most important Intellectual Property (IP) problems which the Pandemic Accord negotiators need to solve is now in danger of being completely...